Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Binimetinib/Encorafenib Combo Approaches European Approval for BRAF+ Melanoma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.

Pembrolizumab Approved in China for Melanoma

July 27th 2018

The China National Drug Administration has approved pembrolizumab (Keytruda) for the treatment of adult patients with unresectable or metastatic melanoma after 1 prior line of therapy.

Melanoma Field Continues to Shift With Targeted Therapy, Immunotherapy Approvals

July 26th 2018

Joseph Stilwill, MD, addresses recent advances in melanoma and the focus of research moving forward.

Dr. Weber Discusses Updated Data for CheckMate-238

July 24th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Dr. Stilwill on Optimal Sequencing in Melanoma

July 24th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses optimal sequencing in melanoma.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Dr. Stilwill on Adjuvant Advances in Melanoma

July 5th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

EU Panel Backs Adjuvant Nivolumab for Melanoma

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease

Dr. Postow on the FDA Approval of Encorafenib and Binimetinib in BRAF-Mutant Melanoma

June 27th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of encorafenib plus binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

June 27th 2018

The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.

FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma

June 25th 2018

The FDA has accepted a supplemental biologics license application for the use of pembrolizumab as an adjuvant treatment for patients with resected, high-risk stage III melanoma.

Dr. Ascierto on the COLUMBUS Trial in Melanoma

June 21st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.

Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma

June 12th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the COLUMBUS trial in patients with BRAF-mutant melanoma.

Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell Carcinoma

June 7th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses cemiplimab in cutaneous squamous cell carcinoma.

NKTR-214/Nivolumab Efficacy Sustained in Phase II Findings

June 5th 2018

Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

May 22nd 2018

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, which is nearly double the historical expectations for patients with the disease.

NCCN Crafts First Guidelines for Uveal Melanoma

May 13th 2018

The unique biological characteristics of uveal melanoma have prompted the National Comprehensive Cancer Network to develop the first set of guidelines for the diagnosis and management of the rare cancer.

Dr. Tarhini Discusses Adjuvant Therapy for Melanoma

May 3rd 2018

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses adjuvant therapy for patients with melanoma.

Dr. Postow on FDA Approval of Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutant Melanoma

May 1st 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.